Abstract:Background: In the past two decades, a large-scale survey of hemoglobinopathies and thalassemia was carried out in mainland China, involving nearly one million people in 28 provinces. The incidences of hemoglobin (Hb) variants, α-thalassemia and β-thalassemia were 0.33%, 2.64% and 0.66%, respectively. The chemical structural analysis identified 67 Hb variants. Among them, 20 are new variants. The analysis of the α-globin gene organization in 111 HbH patients showed 76 cases (68.5%) were of the deletion type, 8 had Hb Constant Spring and the other cases were of non-deletion type. The results of the molecular characterization of more than 200 β-thalassemia alleles showed that the most common types of β-thalassemia mutations in China are CD 41/42 (−4 bp), IVS-II-nt.654 C→T, CD 17 A→T, CD 71/72 (+A) and −28 A→G. Methods: To explore the simple method for molecular diagnosis of β-thalassemia, multiplex allele-specific amplification (MAS-PCR) was used that could simultaneously detect the above five common types of β-thalassemia mutations. Results: Based on the molecular analysis of β-thalassemia intermedia, β-thalassemia homozygotes or compound heterozygotes combined with α-thalassemia, as well as the conjunctive abnormalities of β-thalassemia heterozygote with triplicated haplotype of α-globin genes, were the most common cause of thalassemia intermedia in China. We also used the RT-PCR quantitation method to show that the most common β-thalassemia allele, IVS-II-nt.654 C→T, still produced a small amount (about 15%) of normally spliced β-globin mRNA, therefore, causing β+-thalassemia. In clinical trials of hydroxyurea (HU) treatment for β-thalassemia patients, we found that HU may enhance the expression of the β-globin gene in some patients, leading to an alleviation of clinical symptoms. In the studies of the reversal of aberrant splicing of IVS-II-nt.654 C→T allele by the antisense approach, we constructed a mammalian expression vector that can produce an antisense RNA targeting against the aberrant splice sites of IVS-II-nt.654 C→T pre-mRNA. Conclusions: The results indicated that the antisense RNA produced from the vector could efficiently suppress the aberrant splicing pattern and restore the correct splicing pathway in vitro and in vivo, leading to the improvement of globin chain biosynthesis in thalassemia cells.

Targeted Deletion of 5'HS2 Enhancer of Β-Globin Locus Control Region in K562 Cells.

3’HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

3′HS1 CTCF binding site in human β-globin locus regulates fetal hemoglobin expression

Activation of γ-globin expression by a common variant disrupting IKAROS-binding motif in β-thalassemia

Multi-Omics Analysis in β-Thalassemia Using an HBB Gene-Knockout Human Erythroid Progenitor Cell Model

Human m6A-mRNA and lncRNA epitranscriptomic microarray reveal function of RNA methylation in hemoglobin H-constant spring disease

Long noncoding RNA <i>HBBP1</i> enhances -globin expression through the ETS transcription factor ELK1

Long noncoding RNA HBBP1 enhances γ-globin expression through the ETS transcription factor ELK1

A Genetic Variant Ameliorates Β-Thalassemia Severity by Epigenetic-Mediated Elevation of Human Fetal Hemoglobin Expression

Transcriptome Analyses of β-Thalassemia −28(A>G) Mutation Using Isogenic Cell Models Generated by CRISPR/Cas9 and Asymmetric Single-Stranded Oligodeoxynucleotides (assODNs)

Gene replacement of α-globin with β-globin restores hemoglobin balance in β-thalassemia-derived hematopoietic stem and progenitor cells

Genome-wide analysis of aberrantly expressed lncRNAs and miRNAs with associated co-expression and ceRNA networks in β-thalassemia and hereditary persistence of fetal hemoglobin

The Studies of Hemoglobinopathies and Thalassemia in China--the Experiences in Shanghai Institute of Medical Genetics.

Activation of γ-globin expression by LncRNA-mediated ERF promoter hypermethylation in β-thalassemia

High-level Expression of Hemoglobin A in Human Thalassemic Erythroid Progenitor Cells Following Lentiviral Vector Delivery of an Antisense Snrna

Identification and characterization of CHD4-associated eRNA as a novel modulator of fetal hemoglobin levels in β-thalassemia

Genetic modifications of EGLN1 reactivate HbF production in β0-thalassemia/HbE

[A Study of the Effect of Locus Control Region Elements HS2 and HS3 on Beta-Globin Gene Expression].

Genome-wide methylation and gene-expression analyses in thalassemia

Novel Promoter Mutation (HBB:C.-139_-138del) Associated with β-Thalassemia Trait Detected by Next-Generation Sequencing in Southern China

Characterization of a novel 8.2 kb deletion causing beta-thalassemia